Clinical Trials
19 trialsNCT02367040 2025-10-14
CHRONOS-3
Bayer
Phase 3 Completed
NCT02626455 2024-12-11
CHRONOS-4
Bayer
Phase 3 Terminated
NCT05217914 2024-10-24
A Study to Learn More About Copanlisib Treatment Patterns in People With Indolent Non-Hodgkin Lymphoma, a Type of Cancer That Grows and Spread Slowly and Develops in the Lymphatic System (a Part of Immune System) in Taiwan Under Real-word Conditions
Bayer
Completed
NCT01660451 2024-07-17
Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas
Bayer
Phase 2 Completed
NCT06238583 2024-02-02
Expanded Access to Provide Copanlisib for Patients With Cancer Who Are Experiencing a Positive Response, as Determined by Their Doctors
Bayer
No longer available
NCT03458728 2023-12-04
Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients
Bayer
Phase 1/2 Terminated
NCT02369016 2023-11-18
CHRONOS-2
Bayer
Phase 3 Completed
NCT03735628 2023-10-06
An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors
Bayer
Phase 1 Completed
NCT02342665 2023-01-20
Japanese Phase Ib/II Copanlisib in Relapsed, Indolent B-cell NHL
Bayer
Phase 1/2 Completed
NCT03517956 2022-07-14
ROCOCO
Bayer
Phase 1 Completed
NCT03498430 2021-05-19
Copanlisib Chinese PK Study
Bayer
Phase 1 Completed
NCT03172884 2021-04-28
Study of Copanlisib in Hepatic or Renal Impairment
Bayer
Phase 1 Completed
NCT02253420 2020-12-14
COPANLISIB (BAY80-6946) Drug-drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor and Non-Hodgkin's Lymphoma Patients
Bayer
Phase 1 Completed
NCT02391116 2019-01-04
Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Bayer
Phase 2 Completed
NCT01411410 2017-10-11
Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer
Bayer
Phase 1 Completed
NCT00962611 2017-10-06
BAY80-6946 Open Label, Phase I Study in Patients With Advanced Cancer
Bayer
Phase 1 Completed
NCT02455297 2017-10-02
Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Bayer
Phase 2 Terminated
NCT02155582 2017-06-16
Copanlisib Pharmacodynamic Study
Bayer
Phase 1 Completed
NCT01392521 2015-04-17
Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor Copanlisib With MEK (Mitogen-activated Protein Kinase) Inhibitor Refametinib (BAY86-9766) in Patients With Advanced Cancer
Bayer
Phase 1 Completed